EUVIMEDEUVIMED entdecken
Crossref

A literature review of GLP-1 agonists for the urologist: What do we know so far?

Anayat Ullah, Aliya Ali, Leena Medani, Jack Donati-Bourne

Journal of Clinical Urology · 19.06.2026

DOI: 10.1177/20514158261454811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Urology, online erschienen am 19.06.2026. Verfasst von Anayat Ullah und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Urologists are noting a surge in patients they see who are concurrently taking weight-loss injections, due to exponential rises in prescriptions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for medical and aesthetic purposes. This study aims to summarise current evidence around GLP-1RAs by categorising their unintended benefits and side effects across common urological conditions that may have important ramifications within the field of urology. Materials and methods: Comprehensive literature review using PubMed ® , MEDLINE ® and Google™ Scholar for relevant scientific articles published in English. Manual bibliography search and “ related article ” functions were employed to supplement original searches.

Results

Current knowledge of the collateral impact of GLP-1RA on common urological conditions, such as erectile dysfunction (ED), UTIs, urolithiasis, urological malignancies and hypogonadism is conflicting and predominantly based on weak levels of evidence. Pubmed ® identifies 79 relevant studies relating GLP-1RA to the chosen common urological conditions. There are no randomised controlled trials (RCTs) dedicated to GLP-1RA whose primary outcome pertains directly to urological symptoms and/or sequelae.

Conclusion

GLP-1RA may exert clinically relevant effects across multiple urological domains; however, current evidence is insufficient to draw definitive conclusions. Long-term safety data are lacking. Urologists should remain vigilant while prospective, urology-focused RCTs are urgently needed. Levels of evidence: Not applicable.

Zitieren

APA

Ullah, A., Ali, A., Medani, L., & Donati-Bourne, J. (2026). A literature review of GLP-1 agonists for the urologist: What do we know so far?. Journal of Clinical Urology. https://doi.org/10.1177/20514158261454811

Vancouver

Ullah A, Ali A, Medani L, Donati-Bourne J. A literature review of GLP-1 agonists for the urologist: What do we know so far?. Journal of Clinical Urology. 2026. doi:10.1177/20514158261454811

BibTeX
@article{Ullah2026,
  author = {Ullah, Anayat and Ali, Aliya and Medani, Leena and Donati-Bourne, Jack},
  title = {A literature review of GLP-1 agonists for the urologist: What do we know so far?},
  journal = {Journal of Clinical Urology},
  year = {2026},
  doi = {10.1177/20514158261454811}
}
Kostenlos starten →